The abstract is read at the publisher; the summary is JClub's.
Baseline PD-L1 and TP53 combined with TSG are linked to very-early progression on first-line osimertinib monotherapy in EGFR-mutant NSCLC, with PD-L1 TPS showing the strongest signal.
- Why it matters: New EGFR-targeted regimens raise the need to flag patients likely to progress quickly on osimertinib alone, so upfront treatment can be better matched to risk.
- What they did: In a multicenter retrospective clinical cohort of 1488 advanced EGFR-mutant NSCLC patients treated with first-line osimertinib monotherapy, rwPFS associations were tested using clinicogenomic features; genomic analyses used DFCI and MSKCC plus RNA-seq from Caris Life Science.
- The result: TP53 MUT is associated with shorter rwPFS versus TP53 WT in EGFR ex19del (aHR 1.68, p<0.001) but not L858R (aHR 1.18, p=0.2), while TSG MUT predicts shorter rwPFS overall (aHR 1.5, p=0.01) and PD-L1 TPS is the strongest predictor of very-early rwPFS (AUC=0.16).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.